Systemic antifungal therapy in critically ill patients without invasive fungal infection*

Azoulay, Elie, Dupont, Herve, Tabah, Alexis, Lortholary, Olivier, Stahl, Jean-Paul, Francais, Adrien, Martin, Claude, Guidet, Bertand and Timsit, Jean-Francois (2012) Systemic antifungal therapy in critically ill patients without invasive fungal infection*. Critical Care Medicine, 40 3: 813-822. doi:10.1097/CCM.0b013e318236f297

Author Azoulay, Elie
Dupont, Herve
Tabah, Alexis
Lortholary, Olivier
Stahl, Jean-Paul
Francais, Adrien
Martin, Claude
Guidet, Bertand
Timsit, Jean-Francois
Title Systemic antifungal therapy in critically ill patients without invasive fungal infection*
Journal name Critical Care Medicine   Check publisher's open access policy
ISSN 0090-3493
Publication date 2012-03-01
Year available 2012
Sub-type Article (original research)
DOI 10.1097/CCM.0b013e318236f297
Open Access Status Not Open Access
Volume 40
Issue 3
Start page 813
End page 822
Total pages 10
Place of publication Philadelphia, PA, United States
Publisher Lippincott Williams & Wilkins
Language eng
Formatted abstract
Objective: To determine the number of adult or pediatric intensive care unit patients without documented invasive fungal infection who receive systemic antifungal therapy.

Design: A 1-day cross-sectional cohort study.

Setting: One hundred sixty-nine intensive care units in France and Belgium.

Patients: All patients staying in the participating intensive care units.

Intervention: None.

Measurement and main results: A hierarchical mixed model was used to identify center-based and patient-based determinants of systemic antifungal therapy use. Day 28 mortality was compared in patients with and without systemic antifungal therapy. Two thousand forty-seven patients were recruited. Systemic antifungal therapy was used in 154 (7.5%) patients, including 100 without and 54 with a proven invasive fungal infection. Overall, systemic antifungal therapy consisted of monotherapy of fluconazole (60%), caspofungin (24%), voriconazole (8%), or liposomal amphotericin B (5%). Independent predictors of systemic antifungal therapy included patient-related factors (severity, emergency surgery, malignancy, Candida colonization, and severe sepsis) and center-related factors (hospital with <800 beds, solid organ transplantation activity, higher annual incidence of candidemia, uncontrolled use of fluoroquinolones, and routine systemic antifungal therapy in patients with unresolved documented or undocumented sepsis). The group given systemic antifungal therapy had greater disease severity and higher rates of sepsis and organ failures. Nevertheless, crude 28-day mortality in the systemic antifungal therapy group was not significantly higher than in the group not given systemic antifungal therapy (20% vs. 19.2%; hazard ratio, 0.97 [0.61-1.52]; p = .88).

Conclusions: Systemic antifungal therapy was used in 7.5% of intensive care unit patients. Two-thirds of patients given systemic antifungal therapy had no documented invasive fungal infection. Our results warrant a trial of systemic antifungal therapy in severely ill intensive care unit septic patients without documented invasive fungal infection based on their severity of illness and the presence of Candida colonization. 
Keyword Acute respiratory failure
Mechanical ventilation
Organ failure
Invasive fungal infection
Systemic antifungal therapy
Critically ill patients
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 59 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 65 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 21 Jun 2016, 03:24:22 EST by Alexs Tabah on behalf of Learning and Research Services (UQ Library)